Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   208 Trials   208 Trials   5617 News 


«12...4344454647484950515253...7172»
  • ||||||||||  [VIRTUAL] Real-world outcomes among HER2+ metastatic breast cancer patients with brain metastases (On-Demand) -  Jul 21, 2020 - Abstract #ESMO2020ESMO_626;    
    To account for changes in systemic treatment options, e.g. introduction of trastuzumab emtansine (T-DM1), analysis was conducted in a subgroup of patients diagnosed after January 1, 2016...Trastuzumab + pertuzumab-based therapy was the most common regimen in both 1L and 2L for patients with and without BM...Lapatinib regimens were used more frequently among BM patients, but were used in only 11-15%, depending on line of therapy...Legal entity responsible for the study: Seattle Genetics. Funding: Seattle Genetics.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    [VIRTUAL] Concurrent radiation therapy (RT) and dual HER2 blockade in breast cancer: Assessment of toxicity (On-Demand) -  Jul 21, 2020 - Abstract #ESMO2020ESMO_591;    
    Background The tolerance of the concurrent use of radiotherapy (RT), pertuzumab (P) and trastuzumab (T) is unknown...All pts received Docetaxel followed by P-T as first line treatment and they received 34 cycles (10-85) of P-T...Legal entity responsible for the study: The author. Funding: Has not received any funding.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical, FDA event, Journal:  FDA Approval Summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer. (Pubmed Central) -  Jul 18, 2020   
    Adverse reactions in ≥ 30% of patients receiving pertuzumab were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting. From a regulatory standpoint, the benefits of the addition of pertuzumab to adjuvant treatment outweighed the risks for patients with EBC at high risk of recurrence.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche, Verzenio (abemaciclib) / Eli Lilly
    Trial initiation date, Metastases:  ACCRU-BR-1801: T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) -  Jul 10, 2020   
    P2,  N=126, Not yet recruiting, 
    HER2-targeted therapy has changed the natural history of HER2-positive metastatic breast cancer, with the dual blockade of pertuzumab and trastuzumab, with docetaxel, demonstrating an 8-year landmark overall survival rate of 37%. Initiation date: May 2020 --> May 2021
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
    Enrollment closed, Combination therapy:  Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC (clinicaltrials.gov) -  Jul 1, 2020   
    P2,  N=33, Active, not recruiting, 
    The results indicate that the developed method is suitable for high-sensitive quantification of HER2-ECD in clinical samples. Recruiting --> Active, not recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis toward HER2-positive cancer cells. (Pubmed Central) -  Jun 19, 2020   
    We showed that the degree of FHR4-multivalency within the multimeric immunoconjugates was the key element to efficiently compete and deregulate FH and FH-mediated convertase decay locally on tumour cell surface. FHR4 can thus represent a novel therapeutic molecule, when expressed as a multimeric entity and associated to an anchoring system, to locally shift the complement steady-state towards activation on tumour cell surface.
  • ||||||||||  Clinical, Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi. (Pubmed Central) -  Jun 19, 2020   
    Finally, researchers' interest in tumor microenvironment, particularly tumor-infiltrating lymphocytes, and the major role that signaling pathways, such as the PI3K/AKT/mTOR pathway, play in the development of resistance to anti-HER2 therapies have spurred the development of clinical trials evaluating innovative combinations of anti-HER2 with PD-1/PDL-1, CDK4/6 and PI3K inhibitors. However, several questions remain unresolved, like the optimal management of HER2-positive/HR-positive advanced breast cancer and the identification of predictive biomarkers to better define populations that can benefit most from these new therapies and approaches.